• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RNA干扰沉默hMSH2诱导卵巢癌细胞系OC3/TAX300化疗耐药逆转的研究

[Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300].

作者信息

Wang Aixin, Li Jian, Li Hongxia

机构信息

Department of Obstetrics and Gynecology,Beijing Shijitan Hospital, Capital Medical University,Beijing 100038, China.

Department of Obstetrics and Gynecology,Beijing Shijitan Hospital, Capital Medical University,Beijing 100038, China. Email:

出版信息

Zhonghua Fu Chan Ke Za Zhi. 2014 Mar;49(3):213-7.

PMID:24820308
Abstract

OBJECTIVE

To investigate the reversal effect of hMSH2 small interference RNA(siRNA) on chemo-resistance of ovarian carcinoma cell line OC3/TAX300, explore the clinical significance.

METHODS

The specific hMSH2 siRNA (experimental group) and non-specific hMSH2 siRNA (negative control group) was designed, synthesized and transfected into ovarian carcinoma cell line OC3/TAX300. The expression mRNA and protein levels of hMSH2 were detected by real-time reverse transcription (RT)-PCR and western blot. The cell proliferation was detected by methyl thiazolyl tetrazolium(MTT) method after 12, 24, 48, 72 hours of 2 µg/ml taxol, the apoptosis rate after 24, 48 hours of 2 µg/ml taxol was analyzed by flow cytometry. Morphological changes and ultramicrostructure of cells after 48 hours of 2 µg/ml taxol were observed with transmission electron microscope.

RESULTS

(1) The mRNA levels of hMSH2 were 0.004 ± 0.000, 0.053 ± 0.006 and 0.057 ± 0.012 in experimental group, negative control group and non-infected group, respectively. The protein levels of hMSH2 were 0.19 ± 0.04, 1.00 ± 0.07 and 0.95 ± 0.03 in experimental group, negative control group and non-infected group, respectively. (2) Compared with the non-infected group and the negative control group. The cell proliferation was effectively inhibited after 12, 24, 48, 72 hours of 2 µg/ml taxol (P < 0.05). The cell cycle was arrested at G2/M phase, the apoptotic rate was significantly increased after 24, 48 hours of 2 µg/ml taxol (P < 0.05). The experimental group after 48 hours of 2 µg/ml taxol was found to have more visible cell shrinkage, more serious chromatin margination, nucleus condensation, fragmentation and apoptotic body formation, nucleolus disappeared, markedly swollen mitochondria, mitochondrial cristae disappeared and other signs of apoptosis. While the nucleus was located in the cells of the central and nucleolus is clear, only mild chromatin pyknosis and marginalized, mild swelling of mitochondria in the control group and blank group.

CONCLUSION

siRNA targeting hMSH2 may reverse the chemo-resistance of ovarian carcinoma cell line OC3/TAX300 and may become a treatment or a new direction in the adjuvant therapy of ovarian cancer.

摘要

目的

探讨人错配修复蛋白2(hMSH2)小干扰RNA(siRNA)对卵巢癌细胞系OC3/TAX300化疗耐药的逆转作用,探讨其临床意义。

方法

设计、合成特异性hMSH2 siRNA(实验组)和非特异性hMSH2 siRNA(阴性对照组),转染卵巢癌细胞系OC3/TAX300。采用实时逆转录(RT)-PCR和蛋白质印迹法检测hMSH2的mRNA和蛋白表达水平。用噻唑蓝(MTT)法检测2 μg/ml紫杉醇作用12、24、48、72小时后的细胞增殖情况,用流式细胞术分析2 μg/ml紫杉醇作用24、48小时后的细胞凋亡率。用透射电子显微镜观察2 μg/ml紫杉醇作用48小时后细胞的形态学变化和超微结构。

结果

(1)实验组、阴性对照组和未感染组hMSH2的mRNA水平分别为0.004±0.000、0.053±0.006和0.057±0.012。实验组、阴性对照组和未感染组hMSH2的蛋白水平分别为0.19±0.04、1.00±0.07和0.95±0.03。(2)与未感染组和阴性对照组相比。2 μg/ml紫杉醇作用12、24、48、72小时后细胞增殖受到有效抑制(P<0.05)。细胞周期阻滞于G2/M期,2 μg/ml紫杉醇作用24、48小时后细胞凋亡率显著升高(P<0.05)。2 μg/ml紫杉醇作用48小时后,实验组细胞可见更明显的细胞皱缩、更严重的染色质边集、核浓缩、核碎裂和凋亡小体形成,核仁消失,线粒体明显肿胀,线粒体嵴消失等凋亡征象。而对照组和空白组细胞的细胞核位于中央,核仁清晰,仅见轻度染色质固缩和边缘化,线粒体轻度肿胀。

结论

靶向hMSH2的siRNA可能逆转卵巢癌细胞系OC3/TAX300的化疗耐药,可能成为卵巢癌治疗或辅助治疗的新方向。

相似文献

1
[Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300].RNA干扰沉默hMSH2诱导卵巢癌细胞系OC3/TAX300化疗耐药逆转的研究
Zhonghua Fu Chan Ke Za Zhi. 2014 Mar;49(3):213-7.
2
hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.hMSH2表达与卵巢癌对紫杉醇的耐药性相关,体外抑制hMSH2表达可恢复紫杉醇敏感性。
Oncol Rep. 2014 Nov;32(5):2199-206. doi: 10.3892/or.2014.3430. Epub 2014 Aug 20.
3
[Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].[通过靶向HER-2的小干扰RNA对卵巢癌细胞中HER-2表达的特异性抑制]
Zhonghua Yi Xue Za Zhi. 2006 Mar 7;86(9):619-23.
4
[Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].[抑制素蛋白与卵巢癌紫杉醇耐药性的初步研究]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Dec;37(12):1221-7. doi: 10.3969/j.issn.1672-7347.2012.12.007.
5
[Impact of biological function on ovarian clear cell carcinoma ES2 cell line with ARID1A gene expression down-regulating in vitro].[生物学功能对体外下调ARID1A基因表达的卵巢透明细胞癌ES2细胞系的影响]
Zhonghua Fu Chan Ke Za Zhi. 2016 Mar;51(3):209-15. doi: 10.3760/cma.j.issn.0529-567X.2016.03.009.
6
[The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].[Bcl-2基因沉默对A549细胞系化疗药物敏感性的影响]
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Mar;36(3):191-7.
7
[Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].[MDR1和MDR3基因沉默对A2780/紫杉醇细胞紫杉醇耐药性的逆转作用]
Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
8
[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].[二氢叶酸还原酶基因表达上调在上皮性卵巢癌顺铂耐药中的作用]
Zhonghua Fu Chan Ke Za Zhi. 2015 Nov;50(11):854-60.
9
[Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].[RNA干扰抑制胰岛素样生长因子-1受体对体外细胞生长的影响及对HO8910PM细胞顺铂化疗增敏作用的研究]
Zhonghua Fu Chan Ke Za Zhi. 2008 Jan;43(1):45-9.
10
Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.抑制JAK2可逆转人卵巢癌细胞对紫杉醇的耐药性。
Int J Gynecol Cancer. 2015 Nov;25(9):1557-64. doi: 10.1097/IGC.0000000000000550.